Actiq DCAn oral/transmucosal-“lollipop” delivery system developed to alleviate breakthrough pain in cancer patients. It is also prescribed for off-label indications, including bone injuries, migraines, back pain, cluster headaches, neuropathy, arthritis, and other moderate to severe chronic, non-malignant pain.
The Actiq lollipop is available in 6 different dosage strengths and is indicated for management of breakthrough cancer pain in patients with malignancies who are already receiving opiates for pain control.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.